ARTICLE · 01 JULY 2026
The growing use of combination therapies pairing small molecules with biologics is reshaping drug development, delivering clinically meaningful synergy and improved efficacy. However, as the science advances, so do the intellectual property and regulatory challenges, particularly where multiple stakeholders are involved in bringing these therapies to market.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
